Category: Research

Evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma: Improved outlook for patients with Stage III melanoma

Introduction: Twenty years ago, surgery was the centerpiece of treatment for cutaneous melanoma, including for resectable stage III and IV patients. The arrival of effective systemic therapies in the…

Read more about 'Evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma: Improved outlook for patients with Stage III melanoma'...


Clinicopathologic gene expression profile (CP-GEP) model can reduce number of unnecessary SLNBs performed

Context & aim:  Sentinel lymph node biopsy (SLNB) is an invasive procedure that detects microscopic nodal metastasis, crucial for accurate staging and optimal management. In melanoma, most patients wh…

Read more about 'Clinicopathologic gene expression profile (CP-GEP) model can reduce number of unnecessary SLNBs performed'...


Outcomes of pembrolizumab in advanced melanoma by age and sex

Background: Immune checkpoint inhibitors are standard treatment for advanced melanoma. Pembrolizumab (programmed cell death-1 inhibitor) monotherapy is recommended as first-line treatment. However, r…

Read more about 'Outcomes of pembrolizumab in advanced melanoma by age and sex'...


Clinical perspective on the current burden of melanoma overdiagnosis and its future value for progress in the field of melanoma

Overdiagnosis in melanoma is a nuanced and evolutionary issue. It may appear to be an epidemic from an epidemiological point of view; however, it is important to appreciate all perspectives. We consid…

Read more about 'Clinical perspective on the current burden of melanoma overdiagnosis and its future value for progress in the field of melanoma'...


Phase 1b study of tovorafenib, plozalizumab or vedolizumab plus standard-of-care immune checkpoint inhibitors in patients with advanced melanoma

Background: Novel advanced melanoma therapy combinations may increase treatment efficacy and reduce treatment-related toxicities. Methods: This open-label, nonrandomized, multicenter, phase 1b, 3-a…

Read more about 'Phase 1b study of tovorafenib, plozalizumab or vedolizumab plus standard-of-care immune checkpoint inhibitors in patients with advanced melanoma'...


Serum metabolome serves as diagnostic biomarker and discriminates patients with melanoma from healthy individuals

Melanoma is a deadly cancer with increasing incidence and mortality rates, and biomarkers for diagnosis are urgently needed. The impact of the microbiome, genetic factors, and immunologic markers on d…

Read more about 'Serum metabolome serves as diagnostic biomarker and discriminates patients with melanoma from healthy individuals'...


Review of immune checkpoint inhibitors in non-melanoma malignancies

Over the last decade, immune checkpoint inhibitors (ICIs) have been established as an integral component of the contemporary anticancer armamentarium. In dermatology, ICIs are most established as trea…

Read more about 'Review of immune checkpoint inhibitors in non-melanoma malignancies'...


CtDNA detection after surgery can identify melanoma patients with worse prognosis

Background: Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most …

Read more about 'CtDNA detection after surgery can identify melanoma patients with worse prognosis'...


Therapeutic approaches to mucosal melanoma

Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma arising from mucosal tissues, with distinct genomic and clinical characteristics compared with cutaneous melanoma (CM). Despite thera…

Read more about 'Therapeutic approaches to mucosal melanoma'...